04:33 PM EDT, 10/06/2025 (MT Newswires) -- Yunqi Capital, a 5.1% shareholder in STAAR Surgical ( STAA ) , reaffirmed its opposition to the company's planned merger with Alcon (ALC), saying the $28-per-share deal undervalues STAAR and is "opportunistic."

The investor said recent sales declines in China were temporary and that STAAR's market position and implantable lens technology remain strong. It also criticized executive incentives tied to the deal, including about $24 million in compensation for CEO Stephen Farrell.

Yunqi urged shareholders to vote against the merger, arguing STAAR should focus on cutting costs and restoring growth as an independent company.